Survivin, a cancer target with an emerging role in normal adult tissues
- PMID: 16731740
- DOI: 10.1158/1535-7163.MCT-05-0375
Survivin, a cancer target with an emerging role in normal adult tissues
Abstract
Survivin, an inhibitor of apoptosis protein, is highly expressed in most cancers and associated with chemotherapy resistance, increased tumor recurrence, and shorter patient survival, making antisurvivin therapy an attractive cancer treatment strategy. However, growing evidence indicates that survivin is expressed in normal adult cells, particularly primitive hematopoietic cells, T lymphocytes, polymorphonuclear neutrophils, and vascular endothelial cells, and may regulate their proliferation or survival. In preclinical animal models, targeted antisurvivin therapies show efficacy without overt toxicity. However, consequences of prolonged survivin disruption in normal cells, particularly those associated with continuous renewal, have not been clearly determined. Understanding the role of survivin in normal versus malignant cells will be important in identifying strategies that maximally disrupt survivin in cancer cells with minimal effect on normal tissues. In this review, we summarize the prognostic relevance of survivin in cancer that justifies the pursuit of antisurvivin therapies and discuss differences in survivin expression between normal and cancer cells. We subsequently review expression of survivin in normal adult tissues and evaluate preclinical antisurvivin therapies reported to date in light of emerging roles for survivin in normal physiology, particularly hematopoiesis, angiogenesis, and immune function.
Similar articles
-
Targeting survivin in cancer therapy: fulfilled promises and open questions.Carcinogenesis. 2007 Jun;28(6):1133-9. doi: 10.1093/carcin/bgm047. Epub 2007 Mar 6. Carcinogenesis. 2007. PMID: 17341657 Review.
-
Survivin: a protein with dual roles in mitosis and apoptosis.Int Rev Cytol. 2005;247:35-88. doi: 10.1016/S0074-7696(05)47002-3. Int Rev Cytol. 2005. PMID: 16344111 Review.
-
Survivin is not only a death encounter but also a survival protein for invading tumor cells.Front Biosci. 2007 Jan 1;12:1260-70. doi: 10.2741/2144. Front Biosci. 2007. PMID: 17127378 Review.
-
Transcriptional and post-transcriptional controls of survivin in cancer cells: novel approaches for cancer treatment.J Exp Clin Cancer Res. 2006 Sep;25(3):391-402. J Exp Clin Cancer Res. 2006. PMID: 17167980 Free PMC article. Review.
-
The role of survivin for radiation therapy. Prognostic and predictive factor and therapeutic target.Strahlenther Onkol. 2007 Nov;183(11):593-9. doi: 10.1007/s00066-007-1800-4. Strahlenther Onkol. 2007. PMID: 17960333 Review.
Cited by
-
MicroRNA regulation and therapeutic targeting of survivin in cancer.Am J Cancer Res. 2014 Dec 15;5(1):20-31. eCollection 2015. Am J Cancer Res. 2014. PMID: 25628918 Free PMC article. Review.
-
Weight loss normalizes enhanced expression of the oncogene survivin in visceral adipose tissue and blood leukocytes from individuals with obesity.Int J Obes (Lond). 2021 Jan;45(1):206-216. doi: 10.1038/s41366-020-0630-7. Epub 2020 Jun 16. Int J Obes (Lond). 2021. PMID: 32546857 Free PMC article.
-
Expression of nuclear factor kappa B and survivin in psoriasis.ISRN Dermatol. 2012;2012:257059. doi: 10.5402/2012/257059. Epub 2012 Nov 25. ISRN Dermatol. 2012. PMID: 23227354 Free PMC article.
-
Anti-breast cancer activity of Fine Black ginseng (Panax ginseng Meyer) and ginsenoside Rg5.J Ginseng Res. 2015 Apr;39(2):125-34. doi: 10.1016/j.jgr.2014.09.003. Epub 2014 Oct 18. J Ginseng Res. 2015. PMID: 26045685 Free PMC article.
-
The application, safety, and future of ex vivo immune cell therapies and prognosis in different malignancies.Bioimpacts. 2023;13(6):439-455. doi: 10.34172/bi.2023.27521. Epub 2023 Jul 29. Bioimpacts. 2023. PMID: 38022382 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
